Wealth Enhancement Advisory Services LLC Cuts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Wealth Enhancement Advisory Services LLC reduced its holdings in Alnylam Pharmaceuticals by 64.5%, leaving it with 5,118 shares valued at approximately $1.7 million.
• Alnylam Pharmaceuticals reported strong earnings with an EPS of $0.32, exceeding analysts' expectations, along with a revenue increase of 17.3% year-over-year.
• Analysts have a consensus rating of "Moderate Buy" for the stock, with price targets ranging significantly, including a high of $550 set by UBS Group.

Wealth Enhancement Advisory Services LLC lessened its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 64.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,118 shares of the biopharmaceutical company's stock after selling 9,286 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Alnylam Pharmaceuticals were worth $1,699,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of ALNY. SVB Wealth LLC purchased a new stake in Alnylam Pharmaceuticals during the 1st quarter worth about $27,000. Whipplewood Advisors LLC increased its holdings in shares of Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 71 shares during the last quarter. Bessemer Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 69 shares during the last quarter. Washington Trust Advisors Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 53.5% in the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 61 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB boosted its position in shares of Alnylam Pharmaceuticals by 36.1% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 196 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 52 shares during the period. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Trading Up 0.2%

Shares of ALNY opened at $447.49 on Tuesday. The stock's 50-day moving average is $431.05 and its two-hundred day moving average is $334.15. The stock has a market cap of $58.66 billion, a PE ratio of -181.17 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $484.21. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. During the same period in the previous year, the company earned ($0.13) earnings per share. The company's revenue for the quarter was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ALNY. UBS Group increased their price objective on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Wolfe Research raised Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a research note on Monday, August 4th. Scotiabank raised their price objective on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a "sector outperform" rating in a research note on Friday, August 1st. Truist Financial began coverage on Alnylam Pharmaceuticals in a research report on Monday, July 21st. They set a "buy" rating and a $385.00 price target for the company. Finally, Piper Sandler raised their price target on Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an "overweight" rating in a research report on Friday, August 1st. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $439.58.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, Director Colleen F. Reitan sold 18,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the sale, the director directly owned 775 shares of the company's stock, valued at approximately $362,390. The trade was a 95.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Pushkal Garg sold 1,455 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $458.41, for a total value of $666,986.55. Following the sale, the executive vice president directly owned 20,221 shares in the company, valued at approximately $9,269,508.61. The trade was a 6.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 75,594 shares of company stock valued at $33,968,256. Company insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.